Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma

被引：0
|
作者：
Feerick, Claire L. [1 ,2 ,3 ]
Lynch, Kevin [2 ,3 ,4 ]
Krawczyk, Janusz [2 ,5 ,6 ]
O'Dwyer, Michael [2 ,5 ,6 ]
Ryan, Aideen [1 ,2 ,3 ,4 ,6 ]
机构：
[1] NUI Galway, Sch Med, Coll Med,Nursing & Hlth Sci, Discipline Pharmacol & Therapeut, Galway, Ireland
[2] NUI Galway, Sch Med, Coll Med, Nursing & Hlth Sci, Galway, Ireland
[3] NUI Galway, Regenerat Med Inst REMEDI, Sch Med,Nursing & Hlth Sci, Coll Med, Galway, Ireland
[4] Galway Univ Hosp, Dept Hematol, Galway, Ireland
[5] Blood Canc Network Ireland, Galway, Ireland
[6] NUI Galway, SFI Res Ctr Med Devices, CURAM, Galway, Ireland
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152432
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma
    Mateos, Maria-Victoria
    Granell, Miguel
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Blade, Joan
    Hernandez, Miguel T.
    Martin, Jesus
    Gironella, Mercedes
    Lynch, Mark
    Bleickardt, Eric
    Paliwal, Prashni
    Singhal, Anil
    San-Miguel, Jesus
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (03) : 448 - 456
  • [22] Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma
    Grosicki, Sebastian
    Barchnicka, Agnieszka
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (07) : 621 - 628
  • [23] Combination of low-dose cyclophosphamide and etoposide to mobilize peripheral stem cells before autologous transplantation in patients with multiple myeloma
    Jin, X.
    Zhang, W.
    HIPPOKRATIA, 2022, 26 (01) : 46 - 46
  • [24] Continuous Administration of Low-Dose Cyclophosphamide and Prednisone as a Salvage Treatment for Multiple Myeloma
    Zhou, Fan
    Guo, Lieping
    Shi, Haotian
    Lin, Chenhui
    Hou, Jian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : 51 - 55
  • [25] The impact of genomics to identify novel immunotherapeutic targets in multiple myeloma
    Liu, Enze
    Sudha, Parvathi
    Abu Zaid, Mohammad
    Johnson, Travis
    Chopra, Vivek
    Dos Santos, Cedric
    Nixon, Michael
    Hamidi, Habib
    Suvannasankha, Attaya
    Lee, Kelvin
    Abonour, Rafat
    Walker, Brian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S19 - S20
  • [26] A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Richardson, P.
    Jakubowiak, A.
    Jagannath, S.
    Raab, M.
    Facon, T.
    Vij, R.
    Reece, D.
    White, D.
    Benboubker, L.
    Zonder, J.
    Rossi, J. F.
    Tsao, C.
    Parli, T.
    Kroog, G.
    Singhal, A.
    Lonial, S.
    HAEMATOLOGICA, 2012, 97 : 474 - 474
  • [27] Combination chemotherapy using cyclophosphamide and high dose dexamethasone with or without radiotherapy for the treatment of multiple myeloma.
    Kim, CS
    Lee, MH
    Kim, I
    Moon, Y
    Nahm, CH
    Kim, HC
    Kim, WC
    Loh, JJK
    BLOOD, 2005, 106 (11) : 375B - 375B
  • [28] Novel Combination Treatments in Multiple Myeloma
    Nooka, Ajay K.
    Lonial, Sagar
    ONCOLOGY-NEW YORK, 2016, 30 (05): : 451 - +
  • [29] High dose idarubicin, melphalan and cyclophosphamide for treatment of multiple myeloma
    Schneider, P
    Söhngen, D
    Kobbe, G
    Bauser, U
    Hünerliturkoglu, A
    Heyll, A
    Aul, C
    BONE MARROW TRANSPLANTATION, 1998, 21 : S203 - S203
  • [30] Phase Ib Study of Elotuzumab (HuLuc63) in Combination with Lenalidomide in Relapsed Multiple Myeloma
    Lonial, S.
    Singhal, A.
    Jagannath, S.
    Vij, R.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S20 - S20
12345